Category: ACN Newswire

Everest Medicines Enters into Asset Purchase Agreement with Corxel Pharmaceuticals to Develop and Commercialize LNZ100 in Greater China, Strengthen Presence in Ophthalmology

HONG KONG, Jun 8, 2026 – (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK) announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals (“CORXEL”). Under the agreement, Everest has acquired the rights to develop, manufacture,

More

Alltronics Officially Opens Malaysia Facility

HONG KONG, Jun 5, 2026 – (ACN Newswire via SeaPRwire.com) – Alltronics Holdings Limited (“Alltronics” or the “Group”) (SEHK: 833), a leading manufacturer of electronic products, announced the official opening of its manufacturing facility in Penang, Malaysia. The new operation

More

ERA 2026: HighTide Therapeutics Presents New Findings Supporting HTD1801’s Renoprotective Potential in Oral Presentation

GLASGOW / HONG KONG – Jun 5, 2026 – (ACN Newswire via SeaPRwire.com) – HighTide Therapeutics, Inc. (2511.HK), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today presented new findings on the renoprotective

More

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

HONG KONG, Jun 4, 2026 – (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also

More